Can vitamin D supplementation reduce blood pressure in hypertensive patients?

Editorial note (brief warning): This article was originally published in the past and has been updated according to scientific and divulgative criteria. The information is for informational purposes only and does not replace the advice of your treating physician.

In brief

• Observational evidence shows an association between low levels of 25-OH-vitamin D and higher blood pressure.
• Randomized clinical trials and global meta-analyses do not support a consistent effect of supplementation across the entire population, but some subgroups (hypovitaminosis + hypertensive patients) show signs of benefit.
• Divergent results may depend on dose, duration, initial vitamin D status, and blood pressure measurements (central vs. peripheral).
• Supplementation can be considered as part of an overall nutritional status assessment, not as a primary treatment for hypertension.

Abstract: what does science say?

Vitamin D is a nutrient primarily involved in calcium metabolism, but epidemiological observations have associated lower levels of 25-hydroxyvitamin D (25(OH)D) with higher blood pressure and an increased risk of hypertension. Experimental data suggest plausible mechanisms (modulation of the renin-angiotensin system, endothelial function, and inflammation), however, causal proof is uncertain. Randomized clinical trials and comprehensive meta-analyses do not document a systematic effect of supplementation on blood pressure in general populations; some studies and subgroup analyses indicate modest reductions in blood pressure in people with vitamin D deficiency or in particular clinical settings. Therefore, the hypothesis that vitamin D generally reduces blood pressure is not confirmed: the effect depends on dose, duration, baseline 25(OH)D status, and the type of blood pressure measurement. The evidence requires cautious interpretation and does not justify generalized therapeutic recommendations.

What it means in practice

For those living with hypertension, the practical conclusion is contained and moderate. Measuring vitamin status can be useful when risk factors for deficiency exist (poor sun exposure, malabsorption, advanced age); correcting a documented deficiency remains good practice for bone health and the prevention of related conditions. However, vitamin D supplementation should not be presented as a primary antihypertensive treatment: larger controlled studies do not show a systematic lowering of blood pressure in all treated individuals [1]. Some trials and secondary meta-analyses suggest that hypertensive patients with very low 25(OH)D values may achieve modest reductions in blood pressure with targeted supplementation [8][7].

In practical terms, clinicians may consider assessing vitamin D status in hypertensive patients with clinical signs or risk factors for deficiency, and potentially treat the deficiency according to established nutritional and endocrinological guidelines. Any modification of antihypertensive therapy or clinical decision should be based on individual medical evaluation and objective blood pressure measurements, not solely on vitamin D levels.

Key points to remember

• The observational association between hypovitaminosis D and hypertension does not prove causality.
• Overall randomized trials do not show consistent blood pressure effects of supplementation in general populations. [1]
• Subgroups with documented deficiency may experience modest reductions in blood pressure. [8]
• Administration methods, dose, duration, and measurement (central vs. peripheral) influence results. [4][3]
• Correction of a documented deficiency is justified for general health reasons but does not replace standard antihypertensive therapy.

In-depth section: main evidence and interpretation

Over the past two decades, numerous studies have been conducted on the effect of vitamin D on blood pressure. A large meta-analysis that aggregated individual patient data from randomized trials concluded that, globally, supplementation does not significantly reduce blood pressure in the general population, questioning a direct and generalizable effect of vitamin D as an antihypertensive strategy [1].

However, well-conducted trials such as DAYLIGHT did not find a significant benefit in subjects with prehypertension or mild hypertension treated with high versus low doses of vitamin D [2]. In parallel, studies conducted on already hypertensive patients with hypovitaminosis have yielded variable results: some individual studies report blood pressure improvements, while others show no clinically relevant changes [3][4].

At the genetic level, Mendelian randomization analyses have suggested a possible causal relationship between certain genetic determinants of higher 25(OH)D levels and a lower risk of hypertension, offering mechanistic support for biological plausibility, although these results do not automatically translate into the effectiveness of supplementation as a clinical intervention [5]. Overall, recent reviews highlight heterogeneity: more consistent benefits emerge in subgroups with documented deficiency and in interventions with specific doses and durations, while the generalization of the effect is not supported by aggregated evidence [6][7][8].

Plausible biological mechanisms

The biological plausibility behind a possible blood pressure effect of vitamin D includes the regulation of the renin-angiotensin system, the effect on endothelial function, the modulation of inflammation, and the influence on vascular tone. Experimental studies show that vitamin D can suppress renin expression and improve nitric oxide availability, elements that theoretically can lower blood pressure. However, the translation of molecular effects into measurable clinical outcomes depends on the complex interaction between nutritional status, comorbidities, and concomitant therapies.

Types of studies and quality of evidence

The literature includes observational studies, Mendelian randomization genetic studies, randomized clinical trials, and meta-analyses. Observational studies show associations, useful for generating hypotheses, but subject to confounding. Randomized trials provide stronger evidence on the causality of the intervention; many systematic reviews based on RCTs do not find consistent effects, with exceptions in selected subgroups. Mendelian analyses seek to clarify causal directionality but do not replace targeted RCTs.

Limitations of the evidence

It is important to distinguish between association and causality: observational studies do not prove that vitamin D deficiency causes hypertension. Many trials show variability in doses, formulations, duration, and studied populations, making it difficult to compare results. Often, the trial population does not have very low 25(OH)D levels, which may reduce the possibility of detecting benefits in those who truly need it. Furthermore, different measurements (peripheral vs. central blood pressure, ambulatory vs. clinical) produce non-overlapping results. Finally, statistical heterogeneity in meta-analyses and the limited size of some individual studies limit the strength of the conclusions.

Editorial conclusion

The relationship between vitamin D and blood pressure is scientifically interesting and biologically plausible, but clinical evidence to date does not allow vitamin D supplementation to be considered a proven strategy for hypertension control in the general population. However, it remains prudent and reasonable to identify and correct a documented deficiency for general health reasons. Patients with hypertension should follow established clinical recommendations and discuss any supplementation with their doctor.

Editorial transparency

This article was written in EFV (Easy Friendly Version) style with an institutional approach and based on peer-reviewed scientific literature. The main statements are supported by scientific publications listed at the end. There are no declared editorial conflicts in this text; for information on potential conflicts of the original studies, please refer to the individual cited articles.

Editorial note

Article originally published in the past and updated according to scientific and divulgative criteria. The content is informative in nature and does not replace medical advice. For individual clinical decisions, contact your treating physician.

SCIENTIFIC RESEARCH

1. Effect of Vitamin D Supplementation on Blood Pressure: A Systematic Review and Meta-analysis Incorporating Individual Patient Data. JAMA Intern Med. 2015. https://doi.org/10.1001/jamainternmed.2015.0237
2. Vitamin D therapy in individuals with prehypertension or hypertension: the DAYLIGHT randomized trial. Circulation (DAYLIGHT). 2014. https://doi.org/10.1161/CIRCULATIONAHA.114.011732
3. Styrian Vitamin D Hypertension Trial: Effects of vitamin D on blood pressure and cardiovascular risk factors. Hypertension. 2015. https://doi.org/10.1161/HYPERTENSIONAHA.115.05319
4. Effect of Monthly, High-Dose, Long-Term Vitamin D Supplementation on Central Blood Pressure Parameters: randomized controlled trial substudy. J Am Heart Assoc. 2017. https://doi.org/10.1161/JAHA.117.007466
5. Association of vitamin D status with arterial blood pressure and hypertension risk: a mendelian randomisation study. Lancet Diabetes Endocrinol. 2014. https://doi.org/10.1016/S2213-8587(14)70113-5
6. Meta-analysis: The effect of vitamin D supplementation on blood pressure. Nutrients. 2014. https://doi.org/10.3390/nu6062759
7. Effect of vitamin D supplementation on blood pressure parameters in patients with vitamin D deficiency: systematic review and meta-analysis. J Clin Hypertens (Greenwich) / JASH. 2018. https://doi.org/10.1016/j.jash.2018.04.009
8. Effect of cholecalciferol supplementation on blood pressure in vitamin D deficient individuals: randomized trials meta-analysis. Medicine (Baltimore). 2019. https://doi.org/10.1097/MD.0000000000015284